CROMSOURCE Consolidates Strategic Site Support Service
CROMSOURCE has announced the expansion of its Strategic Site Support Service that can be provided to sites participating in clinical research studies managed by CROMSOURCE on behalf of companies in the pharmaceutical, biotechnology, and medical device industries, or to clients and sites directly.
“As we see greater commitment within our industry to conduct patient centric research in which clinic visits can be done outside of regular working hours or remotely via telemedicine, we are seeing a need to flexibly support sites with strategic services provided to our clients or with the provision of staff directly at sites able to support this new way of working. Considering the effects of the global pandemic, provision of additional resources can also be the difference between sites being able to continue to deliver clinical research projects or having to suspend activities ” said Kerry Dyson, Chief Operating Officer at CROMSOURCE.
For more information, click here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
